.png&w=256&q=75)
3
2
Pakistan
1 year of experience
BS Biochemistry graduate passionate about AI-assisted cancer diagnostics, molecular biology, and healthcare innovation. Interested in combining biological research with emerging AI technologies to develop impactful solutions in early disease detection and precision medicine. Skilled in scientific research, literature review, presentations, and healthcare-focused project collaboration.

MEIA-LAB (Multi-Agent Earnings Intelligence & Alignment Lab) is an end-to-end AI platform that automates the verification of corporate earnings call claims against official SEC filings in real-time. Every quarter, public companies present their financial performance through earnings calls and slide decks, but analysts must manually cross-reference hundreds of pages of SEC disclosures to separate fact from corporate spin—a process that is slow, error-prone, and costly. MEIA-LAB solves this by deploying a team of specialized AI agents orchestrated through LangChain and LangGraph. The ASR Agent uses Whisper to transcribe earnings call audio with high accuracy. The Vision Agent performs layout-aware OCR on presentation slides using PyMuPDF and multimodal LLMs. The Filing Agent retrieves the latest 10-Q and 8-K filings directly from SEC EDGAR and extracts structured financial data. Finally, the Orchestrator cross-examines all sources, scores each management claim for consistency, flags risk discrepancies, and generates source-cited analyst briefs. The platform features a React-based dashboard that surfaces a real-time Consistency Score, a verified claims panel with direct evidence citations, a risk monitor highlighting guidance gaps, and an Evidence Room linking every finding to exact filing pages and transcript lines. All heavy inference workloads including Whisper transcription and high-throughput vector embedding generation for RAG-based filing search via ChromaDB are accelerated on AMD Developer Cloud GPUs using ROCm, delivering massive speedups over CPU execution. MEIA-LAB cuts institutional-grade earnings research from hours to under a minute, helping hedge funds, equity research desks, and compliance teams invest with certainty.
11 Jul 2026

In the rapidly evolving landscape of oncology, researchers and investors are often hindered by fragmented data. Triple-Negative Breast Cancer (TNBC) research is currently siloed across disparate sources—including PubMed, ClinicalTrials.gov, patent databases, and news outlets—making manual monitoring slow, expensive, and error-prone. TNBC Insight AI solves this by aggregating, analyzing, and delivering real-time intelligence through a single, unified dashboard. Built on a robust, enterprise-grade architecture using React and a Python/Flask API, our platform leverages OpenAI’s NLP to distill complex publications and trial reports into concise, actionable briefs. The system automates the entire intelligence workflow, allowing users to track drug pipelines, monitor trial enrollment, identify funding signals, and visualize patent landscapes in real-time. By automating these tasks, TNBC Insight AI enables teams to move at the speed of science, ensuring that critical competitive moves and emerging research trends are never missed.
31 May 2026